Take home message Eli Lilly reported on 21 May 2026 that retatrutide produced an average weight loss of up to 30.3% in its Phase 3 TRIUMPH-1 trial, the largest figure reported so far for a weight-loss injection
Our MeAgain app helps by consolidating dose timing, side effects, nutrition patterns, and progress metrics in one place, making it easier to spot when results diverge from expectations or when dosing inconsistencies affect outcomes
To learn more about plasma or platelet donation while living with diabetes, contact us directly or continue reading below
Bright, juicy lippies are a staple of our makeup bags, so it comes as no surprise that none of us can pass up the chance to road-test Peach Cs Peach Holiday Tint collection, especially after glowing endorsements of the brands Peach Cotton Blushers from our editor Romy and from Kennie J.D
Online orders cannot be exchanged or returned in a physical store
In 2025, the company reported a solid +8.62% YoY revenue growth, supported by its oncology franchise: Tagrisso ($7.25B) continues to lead in lung cancer with strong global adoption, Imfinzi ($6.06B) is expanding across multiple cancer indications, and Calquence ($3.51B) is gaining traction in hematologic cancers - reflecting sustained momentum in its cancer portfolio
/sc-assets/prd/practices/cdcd65da-a892-465a-aa2c-48d5c1f8134f/Tirzepatide%20vial.png)
